Pfizer Cancer Drug Efficacy Triggers Early Phase III Trial Termination
This article was originally published in The Pink Sheet Daily
Executive Summary
Angiogenesis inhibitor SU11248 shows significant efficacy in Gleevec-resistant gastrointestinal stromal tumors; Pfizer plans NDA submission for GIST and renal cell carcinoma by end of 2005. A Phase III trial in second-line renal cell carcinoma is ongoing.
You may also be interested in...
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
Filing Timeline Unclear After Sutent Trial In Rare Pancreatic Cancer Stops Early
Phase III study, halted for efficacy, tested the tyrosine kinase inhibitor in a disease type that strikes about 30 to 50 patients per million of the total afflicted.
Sutent Shows Benefit In Rare Pancreatic Cancer; Pfizer Stops Phase III Early
Pfizer stopped a Phase III trial for its cancer drug Sutent (sunitinib) early after the data safety monitoring board said the compound showed significant benefit in a rare form of pancreatic cancer, the company announced March 12